Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity.

ABSTRACT

Covalent inhibitors of oncogenic KRASG12C have demonstrated impressive clinical responses; however, therapeutic resistance has been commonly observed. In this issue, Zhang and colleagues demonstrate that small molecule KRASG12C inhibitors can generate haptenated major histocompatibility complex (MHC) class Ipeptide complexes, which represent attractive targets for immune-based therapies to combat pharmacologic resistance.